Agilent Technologies (A) 주식 개요
는 전 세계 생명 과학, 진단 및 응용 화학 시장에 응용 분야 중심의 솔루션을 제공합니다. 자세히 보기
강점
위험 분석
우리의 위험 점검에서 A에 대한 위험이 감지되지 않았습니다.
A Community Fair Values
Create NarrativeSee what 47 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Pharmaceuticals & Biotech opportunity
Agilent Technologies, Inc. 경쟁사
가격 이력 및 성과
| 과거 주가 | |
|---|---|
| 현재 주가 | US$117.69 |
| 52주 최고가 | US$160.27 |
| 52주 최저가 | US$104.79 |
| 베타 | 1.22 |
| 1개월 변동 | 2.48% |
| 3개월 변동 | -9.22% |
| 1년 변동 | 9.46% |
| 3년 변동 | -8.10% |
| 5년 변동 | -8.51% |
| IPO 이후 변동 | 175.30% |
최근 뉴스 및 업데이트
내러티브 업데이트 • Apr 25
A: New Diagnostic Approvals And Buybacks Will Support Long Term Upside
Analysts have trimmed their price target on Agilent Technologies by about $1 to $160.69, reflecting slightly adjusted views on fair value, discount rate, revenue growth, profit margin, and future P/E assumptions. What's in the News The Supreme Court of the United States denied Agilent Technologies' petition related to two CRISPR guide RNA patents, leaving in place prior rulings that found all claims of the patents unpatentable.내러티브 업데이트 • Apr 09
A: New Diagnostic Expansion And Guidance Will Support Long Term Upside
Analysts have slightly reduced their price target on Agilent Technologies by about $1, citing updated assumptions for fair value, discount rate, revenue growth, profit margin, and future P/E. They indicate that the overall outlook remains largely intact.Recent updates
내러티브 업데이트 • Apr 25
A: New Diagnostic Approvals And Buybacks Will Support Long Term Upside
Analysts have trimmed their price target on Agilent Technologies by about $1 to $160.69, reflecting slightly adjusted views on fair value, discount rate, revenue growth, profit margin, and future P/E assumptions. What's in the News The Supreme Court of the United States denied Agilent Technologies' petition related to two CRISPR guide RNA patents, leaving in place prior rulings that found all claims of the patents unpatentable.내러티브 업데이트 • Apr 09
A: New Diagnostic Expansion And Guidance Will Support Long Term Upside
Analysts have slightly reduced their price target on Agilent Technologies by about $1, citing updated assumptions for fair value, discount rate, revenue growth, profit margin, and future P/E. They indicate that the overall outlook remains largely intact.내러티브 업데이트 • Mar 26
A: New Diagnostic Approval Will Drive Upside For Long Term Outlook
Analysts have made a slight trim to their price target for Agilent Technologies to about $163.19 from around $163.29, citing updated assumptions for revenue growth, profit margins and a somewhat lower future P/E multiple. What's in the News The FDA approved Agilent's PD-L1 IHC 22C3 pharmDx, Code SK006, as a companion diagnostic to help identify first line patients with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma who may be eligible for treatment with KEYTRUDA, adding a seventh companion diagnostic indication for this assay (Key Developments).내러티브 업데이트 • Mar 11
A: New Diagnostic Approvals And Digital Pathology Expansion Will Drive Upside
Analysts have trimmed their price target on Agilent Technologies to about $163 from roughly $170, citing modest tweaks to their models, including slightly adjusted revenue growth, discount rate, profit margin, and future P/E assumptions. What's in the News Agilent issued earnings guidance for fiscal Q2 2026, with revenue expected in the range of $1.79b to $1.82b, framed as approximately 7% to 9% reported growth and 4% to 5.5% core growth (company guidance).Seeking Alpha • Mar 10
Why Agilent Technologies Just Paid $950 Million For Biocare Medical
Summary Agilent Technologies (A) acquires Biocare Medical for $950M to expand into high-growth pathology and cancer diagnostics, enhancing recurring consumables revenue streams. A trades below historical valuation multiples, presenting an opportunity if management executes on diagnostics expansion and leverages its global distribution to scale Biocare’s offerings. 1Q26 results showed 7% reported revenue growth to $1.80B, with non-GAAP EPS up 4% year-over-year, and management raised FY26 guidance for both revenue and EPS. The Biocare deal accelerates Agilent’s shift toward higher-margin, recurring revenue, with management expecting positive EPS contribution within 12 months post-close. Read the full article on Seeking Alpha내러티브 업데이트 • Feb 25
A: New Diagnostic Approvals Will Support Measured Upside Ahead
Analysts reaffirm a price target of $169.67 for Agilent Technologies, citing largely unchanged assumptions for the discount rate, revenue growth, profit margin, and future P/E. These factors together keep their valuation framework intact.내러티브 업데이트 • Feb 10
A: New Digital Pathology And Board Declassification Will Support Measured Upside Ahead
Analysts have modestly trimmed their price target on Agilent Technologies to reflect slightly higher discount rate assumptions and a lower future P/E, while still incorporating steady revenue growth and a marginally stronger profit margin outlook. What's in the News Agilent plans to ask shareholders at the March 18, 2026 AGM to approve an amendment to its Third Amended and Restated Certificate of Incorporation that would declassify the board of directors over three years, shifting toward annual director elections (Key Developments).내러티브 업데이트 • Jan 26
A: New Digital Pathology And Buybacks Will Support Measured Upside Ahead
Analysts have nudged their price target on Agilent Technologies slightly higher to about US$170, citing updated assumptions around fair value, discount rates, revenue growth, profit margins and future P/E, which collectively support a modest upward revision. What's in the News Agilent launched the S540 MD Slide Scanner System for whole slide imaging in key European markets, adding a high throughput digital pathology scanner with capacity for 540 slides and AI assisted tissue detection to its portfolio (Product Related Announcements).내러티브 업데이트 • Jan 11
A: New CFO And Capital Returns Will Support Measured Upside Ahead
Analysts have nudged their price target for Agilent Technologies slightly lower to US$168.59 from US$169.44, citing small adjustments to their fair value estimate, discount rate, revenue growth outlook, profit margin assumptions, and future P/E expectations. What's in the News Agilent outlined fiscal first quarter 2026 revenue guidance of US$1.79b to US$1.82b and fiscal 2026 revenue guidance of US$7.3b to US$7.4b, with both ranges expressed in reported and core terms (Corporate guidance).분석 기사 • Dec 18
Agilent Technologies (NYSE:A) Is Increasing Its Dividend To $0.255
Agilent Technologies, Inc. ( NYSE:A ) has announced that it will be increasing its dividend from last year's comparable...내러티브 업데이트 • Dec 15
A: New Leadership And Compliance Software Will Support Measured Upside Ahead
Analysts have nudged their average price target on Agilent Technologies higher by about $2 to roughly $169.44, citing slightly faster expected revenue growth and a modestly lower discount rate that more than offset a small downward revision to long term profit margins. What's in the News Launched 21 CFR Part 11 compliant software for the xCELLigence RTCA eSight system, enabling secure deployment in GMP manufacturing and QC labs with features such as secure logins, e-signatures, and full audit trails (Key Developments).내러티브 업데이트 • Nov 30
A: New Diagnostic Solutions And Leadership Will Shape Measured Prospects Ahead
Analysts have raised their price target for Agilent Technologies from $152.33 to $167.57, citing modestly higher expectations for revenue growth and valuation metrics as the primary reasons for the change. What's in the News Agilent Technologies provided earnings guidance for fiscal Q1 2026, expecting revenue in the range of $1.79 billion to $1.82 billion, up 6% to 8% reported and 4% to 6% core.분석 기사 • Nov 27
Agilent Technologies, Inc. (NYSE:A) Analysts Are Pretty Bullish On The Stock After Recent Results
It's been a good week for Agilent Technologies, Inc. ( NYSE:A ) shareholders, because the company has just released its...내러티브 업데이트 • Nov 16
A: Product Launches And Diagnostic Approval Will Support Balanced Outlook
Narrative Update: Agilent Technologies Analyst Price Target Revision Analysts have raised their price target for Agilent Technologies from $149.90 to $152.33. This change reflects modest upward revisions in projected revenue growth and a slightly higher expected future valuation multiple.내러티브 업데이트 • Nov 01
A: Global Healthcare Trends And New Diagnostic Solutions Will Shape Future Performance
Analysts have slightly raised their price target for Agilent Technologies from $148.57 to $149.90, citing stable fundamentals and a modest valuation adjustment. What's in the News Adam S.내러티브 업데이트 • Oct 18
Global Healthcare Demand And PFAS Testing Will Drive Analytical Progress
Analysts have raised their price target for Agilent Technologies from $140.97 to $148.57, citing improved revenue growth prospects and higher expected profit margins as key drivers behind the upward revision. What's in the News Announced launch of Insight Series Alarm Resolution Systems, which enhance airport security checkpoints with advanced liquid explosive detection and adaptability to changing regulations (Product Related Announcements).내러티브 업데이트 • Oct 04
Global Healthcare Demand And PFAS Testing Will Drive Analytical Progress
Agilent Technologies received a modest analyst price target increase from $138.83 to $140.97. This reflects analysts' expectations for stable growth and slightly improved long-term valuation metrics.내러티브 업데이트 • Sep 16
Global Healthcare Demand And PFAS Testing Will Drive Analytical Progress
Agilent Technologies’ fair value estimates have remained stable, as reflected by marginal changes in both the consensus analyst price target (up slightly to $138.83) and the forward P/E (now 27.33x). What's in the News Raised full-year 2025 revenue guidance to $6.91–$6.93 billion, up 6.2–6.5% reported and 4.3–4.6% core, reflecting a $150 million increase at the midpoint and 1.5 points higher core growth.분석 기사 • Aug 03
Estimating The Intrinsic Value Of Agilent Technologies, Inc. (NYSE:A)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Agilent Technologies fair value estimate is US$114 With US$114...분석 기사 • Jul 01
What Is Agilent Technologies, Inc.'s (NYSE:A) Share Price Doing?
Today we're going to take a look at the well-established Agilent Technologies, Inc. ( NYSE:A ). The company's stock saw...Seeking Alpha • Apr 24
City Office REIT (RED PFD SER A): A High Yield, Deep Value Opportunity Worth Latching Onto
Summary City Office REIT's Series A Preferred Shares offer a tempting yield despite recent accounting losses and systemic pressures, suggesting a potential buying opportunity. The shares are cumulative, redeemable, and fixed, ensuring eventual dividend payments, though call risk and financial restructuring are potential concerns. The REIT's fundamentals, including an 85.8% occupancy rate and sector diversification, support sustainability, with positive economic profitability and AFFO figures. Despite macroeconomic risks, Series A's deep discount and commendable yield, along with manageable leverage ratios, led to us deeming it a 'Buy.' Read the full article on Seeking AlphaSeeking Alpha • Apr 07
Tariffs And Tactics: Agilent's Path Through Trade Disruption
Summary The April 2025 "Liberation Day" tariffs impose a 10% baseline tariff on all imports and additional surcharges, significantly impacting Agilent Technologies' cost structure and supply chain. Agilent's diversified global manufacturing footprint and strategic localization in China help mitigate some tariff impacts, but higher costs and competitive pressures remain concerns. Despite initial projections of modest financial impact, prolonged tariffs could necessitate further operational shifts, including relocating production and localizing R&D to maintain market access. Agilent's strong brand, advanced technology, and flexible supply chain position it to navigate tariff challenges, with potential long-term benefits from a more resilient global network. Read the full article on Seeking AlphaSeeking Alpha • Mar 01
Agilent Technologies: Recent Price Weakness Makes This Stock A Buy
Summary Agilent Technologies, a leader in life sciences and diagnostics, has a market cap of $38B and a 10-year CAGR of 13.6%. Key financial metrics: consistent revenue growth, stable gross profit margin above 50%, and a robust return on invested capital, despite some fluctuations. The stock fell too far after its recent earnings report, making it too good to pass up at its current level. Read the full article on Seeking Alpha주주 수익률
| A | US Life Sciences | US 시장 | |
|---|---|---|---|
| 7D | 5.7% | 4.3% | 3.2% |
| 1Y | 9.5% | 7.9% | 31.0% |
수익률 대 산업: A은 지난 1년 동안 7.9%의 수익을 기록한 US Life Sciences 산업과 동일한 성과를 보였습니다.
수익률 대 시장: A은 지난 1년 동안 31%를 기록한 US 시장보다 저조한 성과를 냈습니다.
주가 변동성
| A volatility | |
|---|---|
| A Average Weekly Movement | 4.2% |
| Life Sciences Industry Average Movement | 8.1% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 3.2% |
안정적인 주가: A는 지난 3개월 동안 US 시장에 비해 주가 변동성이 크지 않았습니다.
시간에 따른 변동성: A의 주간 변동성(4%)은 지난 1년 동안 안정적이었습니다.
회사 소개
| 설립 | 직원 수 | CEO | 웹사이트 |
|---|---|---|---|
| 1999 | 18,000 | Padraig McDonnell | www.agilent.com |
는 전 세계 생명 과학, 진단 및 응용 화학 시장에 응용 분야 중심의 솔루션을 제공합니다. 이 회사는 세 가지 부문을 통해 운영됩니다: 생명 과학 및 진단 시장, 애질런트 크로스랩, 응용 시장입니다. 생명 과학 및 진단 시장 부문에서는 액체 크로마토그래피 시스템 및 구성 요소와 액체 크로마토그래피 질량 분석 시스템을 제공합니다.
Agilent Technologies, Inc. 기초 지표 요약
| A 기초 통계 | |
|---|---|
| 시가총액 | US$33.21b |
| 순이익 (TTM) | US$1.29b |
| 매출 (TTM) | US$7.07b |
25.8x
주가수익비율(P/E)4.7x
주가매출비율(P/S)A는 고평가되어 있습니까?
공정 가치 및 평가 분석 보기순이익 및 매출
| A 손익계산서 (TTM) | |
|---|---|
| 매출 | US$7.07b |
| 매출원가 | US$3.37b |
| 총이익 | US$3.70b |
| 기타 비용 | US$2.41b |
| 순이익 | US$1.29b |
최근 보고된 실적
Jan 31, 2026
다음 실적 발표일
May 27, 2026
| 주당순이익(EPS) | 4.56 |
| 총이익률 | 52.30% |
| 순이익률 | 18.26% |
| 부채/자본 비율 | 48.6% |
A의 장기 실적은 어땠습니까?
과거 실적 및 비교 보기배당
0.9%
현재 배당 수익률22%
배당 성향기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/05/06 12:28 |
| 종가 | 2026/05/06 00:00 |
| 수익 | 2026/01/31 |
| 연간 수익 | 2025/10/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Agilent Technologies, Inc.는 34명의 분석가가 다루고 있습니다. 이 중 17명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Catherine Ramsey Schulte | Baird |
| Charles Butler | Barclays |
| Luke Sergott | Barclays |